Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 102 articles:
HTML format
Text format



Single Articles


    June 2018
  1. PAJARES B, Porta J, Porta JM, Sousa CF, et al
    Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.
    BMC Cancer. 2018;18:647.
    PubMed     Text format     Abstract available


  2. XINTAROPOULOU C, Ward C, Wise A, Queckborner S, et al
    Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.
    BMC Cancer. 2018;18:636.
    PubMed     Text format     Abstract available


    May 2018
  3. LEE JY, Kim S, Kim YT, Lim MC, et al
    Changes in ovarian cancer survival during the 20 years before the era of targeted therapy.
    BMC Cancer. 2018;18:601.
    PubMed     Text format     Abstract available


    April 2018
  4. BAUERSFELD SP, Kessler CS, Wischnewsky M, Jaensch A, et al
    The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.
    BMC Cancer. 2018;18:476.
    PubMed     Text format     Abstract available


  5. SEEBACHER V, Polterauer S, Reinthaller A, Koelbl H, et al
    AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer - a retrospective multi-centre study.
    BMC Cancer. 2018;18:447.
    PubMed     Text format     Abstract available


  6. ZHU Y, Zhou S, Liu Y, Zhai L, et al
    Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review.
    BMC Cancer. 2018;18:443.
    PubMed     Text format     Abstract available


  7. TANG Z, Yang J, Wang X, Zeng M, et al
    Active DNA end processing in micronuclei of ovarian cancer cells.
    BMC Cancer. 2018;18:426.
    PubMed     Text format     Abstract available


    March 2018
  8. LE PAGE C, Rahimi K, Kobel M, Tonin PN, et al
    Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    BMC Cancer. 2018;18:347.
    PubMed     Text format     Abstract available


  9. ZHAO D, Wang X, Zhang W
    GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
    BMC Cancer. 2018;18:328.
    PubMed     Text format     Abstract available


  10. HANLEY GE, McAlpine JN, Miller D, Huntsman D, et al
    A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    BMC Cancer. 2018;18:254.
    PubMed     Text format     Abstract available


    February 2018
  11. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Text format     Abstract available


    January 2018
  12. O'DONNELL T, Christie EL, Ahuja A, Buros J, et al
    Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
    BMC Cancer. 2018;18:87.
    PubMed     Text format     Abstract available


    December 2017
  13. DU J, Shi HR, Ren F, Wang JL, et al
    Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    BMC Cancer. 2017;17:851.
    PubMed     Text format     Abstract available


  14. MIAO F, Zhang X, Cao Y, Wang Y, et al
    Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells.
    BMC Cancer. 2017;17:838.
    PubMed     Text format     Abstract available


  15. SMITS S, Boivin J, Menon U, Brain K, et al
    Influences on anticipated time to ovarian cancer symptom presentation in women at increased risk compared to population risk of ovarian cancer.
    BMC Cancer. 2017;17:814.
    PubMed     Text format     Abstract available


    September 2017
  16. JAMES FR, Jiminez-Linan M, Alsop J, Mack M, et al
    Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.
    BMC Cancer. 2017;17:657.
    PubMed     Text format     Abstract available


  17. SMEBYE ML, Agostini A, Johannessen B, Thorsen J, et al
    Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
    BMC Cancer. 2017;17:642.
    PubMed     Text format     Abstract available


    August 2017
  18. CHAN KKL, Siu MKY, Jiang YX, Wang JJ, et al
    Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
    BMC Cancer. 2017;17:606.
    PubMed     Text format     Abstract available


  19. TONG JG, Valdes YR, Sivapragasam M, Barrett JW, et al
    Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.
    BMC Cancer. 2017;17:594.
    PubMed     Text format     Abstract available


  20. OHSUGA T, Yamaguchi K, Kido A, Murakami R, et al
    Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    BMC Cancer. 2017;17:580.
    PubMed     Text format     Abstract available


    July 2017
  21. MAATTA KM, Nurminen R, Kankuri-Tammilehto M, Kallioniemi A, et al
    Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    BMC Cancer. 2017;17:496.
    PubMed     Text format     Abstract available


  22. EOH KJ, Yoon JW, Lee JY, Nam EJ, et al
    A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy.
    BMC Cancer. 2017;17:481.
    PubMed     Text format     Abstract available


  23. SWIATLY A, Horala A, Hajduk J, Matysiak J, et al
    MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
    BMC Cancer. 2017;17:472.
    PubMed     Text format     Abstract available


    June 2017
  24. GEORGE A, McLachlan J, Tunariu N, Della Pepa C, et al
    The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
    BMC Cancer. 2017;17:456.
    PubMed     Text format     Abstract available


  25. WANG S, Wei H, Zhang S
    Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion.
    BMC Cancer. 2017;17:455.
    PubMed     Text format     Abstract available


  26. YANG J, Zhou Y, Ng SK, Huang KC, et al
    Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    BMC Cancer. 2017;17:422.
    PubMed     Text format     Abstract available


    May 2017
  27. ZANOTTI L, Romani C, Tassone L, Todeschini P, et al
    MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
    BMC Cancer. 2017;17:366.
    PubMed     Text format     Abstract available


  28. SCHULER-TOPRAK S, Moehle C, Skrzypczak M, Ortmann O, et al
    Effect of estrogen receptor beta agonists on proliferation and gene expression of ovarian cancer cells.
    BMC Cancer. 2017;17:319.
    PubMed     Text format     Abstract available


  29. YE S, He T, Liang S, Chen X, et al
    Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma.
    BMC Cancer. 2017;17:317.
    PubMed     Text format     Abstract available


  30. LEVAN K, Mehryar M, Mateoiu C, Albertsson P, et al
    Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
    BMC Cancer. 2017;17:303.
    PubMed     Text format     Abstract available


    April 2017
  31. LIU Y, Chen S, Zheng C, Ding M, et al
    The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
    BMC Cancer. 2017;17:285.
    PubMed     Text format     Abstract available


    March 2017
  32. PETERS IT, van der Steen MA, Huisman BW, Hilders CG, et al
    Morphological and phenotypical features of ovarian metastases in breast cancer patients.
    BMC Cancer. 2017;17:206.
    PubMed     Text format     Abstract available


    February 2017
  33. TILBURY KB, Campbell KR, Eliceiri KW, Salih SM, et al
    Stromal alterations in ovarian cancers via wavelength dependent Second Harmonic Generation microscopy and optical scattering.
    BMC Cancer. 2017;17:102.
    PubMed     Text format     Abstract available


  34. GANSMO LB, Bjornslett M, Halle MK, Salvesen HB, et al
    MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
    BMC Cancer. 2017;17:97.
    PubMed     Text format     Abstract available


    January 2017
  35. MIYAMOTO S, Yotsumoto F, Ueda T, Fukami T, et al
    BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.
    BMC Cancer. 2017;17:89.
    PubMed     Text format     Abstract available


  36. VALTCHEVA N, Lang FM, Noske A, Samartzis EP, et al
    Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    BMC Cancer. 2017;17:66.
    PubMed     Text format     Abstract available


  37. AYYAGARI VN, Hsieh TJ, Diaz-Sylvester PL, Brard L, et al
    Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
    BMC Cancer. 2017;17:49.
    PubMed     Text format     Abstract available


  38. BRANDT S, Samartzis EP, Zimmermann AK, Fink D, et al
    Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    BMC Cancer. 2017;17:44.
    PubMed     Text format     Abstract available


  39. TEMPFER CB, Hartmann F, Hilal Z, Rezniczek GA, et al
    Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report.
    BMC Cancer. 2017;17:26.
    PubMed     Text format     Abstract available


    December 2016
  40. MAISTRO S, Teixeira N, Encinas G, Katayama ML, et al
    Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    BMC Cancer. 2016;16:934.
    PubMed     Text format     Abstract available


    November 2016
  41. NAKAMURA H, Nagasaka K, Kawana K, Taguchi A, et al
    Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.
    BMC Cancer. 2016;16:897.
    PubMed     Text format     Abstract available


  42. YU X, Zhang Y, Chen H
    LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    BMC Cancer. 2016;16:846.
    PubMed     Text format     Abstract available


  43. SHEN CC, Hu LY, Yang AC, Chiang YY, et al
    Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study.
    BMC Cancer. 2016;16:839.
    PubMed     Text format     Abstract available


    October 2016
  44. YE H, Liu X, Sun J, Zhu S, et al
    Enhanced therapeutic efficacy of LHRHa-targeted brucea javanica oil liposomes for ovarian cancer.
    BMC Cancer. 2016;16:831.
    PubMed     Text format     Abstract available


  45. ORNELAS A, McCullough CR, Lu Z, Zacharias NM, et al
    Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models.
    BMC Cancer. 2016;16:824.
    PubMed     Text format     Abstract available


  46. HICKS DA, Galimanis CE, Webb PG, Spillman MA, et al
    Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration.
    BMC Cancer. 2016;16:788.
    PubMed     Text format     Abstract available


    February 2016
  47. NARENDRULA R, Mispel-Beyer K, Guo B, Parissenti AM, et al
    RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
    BMC Cancer. 2016;16:146.
    PubMed     Text format     Abstract available


    January 2016
  48. FENG Z, Wen H, Bi R, Duan Y, et al
    Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    BMC Cancer. 2016;16:43.
    PubMed     Text format     Abstract available


  49. SCHMID G, Notaro S, Reimer D, Abdel-Azim S, et al
    Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
    BMC Cancer. 2016;16:102.
    PubMed     Text format     Abstract available


  50. WU GJ, Zeng GF
    METCAM/MUC18 is a novel tumor and metastasis suppressor for the human ovarian cancer SKOV3 cells.
    BMC Cancer. 2016;16:136.
    PubMed     Text format     Abstract available


  51. KOUSSOUNADIS A, Langdon SP, Um I, Kay C, et al
    Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
    BMC Cancer. 2016;16:205.
    PubMed     Text format     Abstract available


  52. HIJAZ M, Das S, Mert I, Gupta A, et al
    Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
    BMC Cancer. 2016;16:220.
    PubMed     Text format     Abstract available


  53. ZHOU J, Zhao M, Tang Y, Wang J, et al
    The milk-derived fusion peptide, ACFP, suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways.
    BMC Cancer. 2016;16:246.
    PubMed     Text format     Abstract available


  54. STAUDIGL C, Pfeiler G, Hrauda K, Renz R, et al
    Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect".
    BMC Cancer. 2016;16:436.
    PubMed     Text format     Abstract available


  55. SAMARDZIJA C, Luwor RB, Quinn MA, Kannourakis G, et al
    Coalition of Oct4A and beta1 integrins in facilitating metastasis in ovarian cancer.
    BMC Cancer. 2016;16:432.
    PubMed     Text format     Abstract available


  56. XIAO X, Yang G, Bai P, Gui S, et al
    Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
    BMC Cancer. 2016;16:582.
    PubMed     Text format     Abstract available


  57. COZZI GD, Samuel JM, Fromal JT, Keene S, et al
    Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.
    BMC Cancer. 2016;16:612.
    PubMed     Text format     Abstract available


  58. KIM MK, Caplen N, Chakka S, Hernandez L, et al
    Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.
    BMC Cancer. 2016;16:678.
    PubMed     Text format     Abstract available


  59. BLOK F, Roes EM, van Leenders GJ, van Beekhuizen HJ, et al
    The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
    BMC Cancer. 2016;16:18.
    PubMed     Text format     Abstract available


  60. PARK B, Park S, Shin HR, Shin A, et al
    Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea.
    BMC Cancer. 2016;16:5.
    PubMed     Text format     Abstract available


  61. LI X, Shen B, Chen Q, Zhang X, et al
    Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.
    BMC Cancer. 2016;16:251.
    PubMed     Text format     Abstract available


  62. CHANG YH, Li WH, Chang Y, Peng CW, et al
    Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
    BMC Cancer. 2016;16:235.
    PubMed     Text format     Abstract available


  63. DROESER RA, Mechera R, Daster S, Weixler B, et al
    MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.
    BMC Cancer. 2016;16:639.
    PubMed     Text format     Abstract available


  64. NOTARO S, Reimer D, Fiegl H, Schmid G, et al
    Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
    BMC Cancer. 2016;16:589.
    PubMed     Text format     Abstract available


  65. WHICKER ME, Lin ZP, Hanna R, Sartorelli AC, et al
    MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    BMC Cancer. 2016;16:550.
    PubMed     Text format     Abstract available


  66. SMOGELI E, Davidson B, Cvancarova M, Holth A, et al
    L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
    BMC Cancer. 2016;16:596.
    PubMed     Text format     Abstract available


    May 2015
  67. MACKENZIE R, Kommoss S, Winterhoff BJ, Kipp BR, et al
    Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    BMC Cancer. 2015;15:415.
    PubMed     Text format     Abstract available


    April 2015
  68. QIAN Q, You Y, Yang J, Cao D, et al
    Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study.
    BMC Cancer. 2015;15:270.
    PubMed     Text format     Abstract available


  69. CABURET S, Anttonen M, Todeschini AL, Unkila-Kallio L, et al
    Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes.
    BMC Cancer. 2015;15:251.
    PubMed     Text format     Abstract available


    March 2015
  70. JOZWIK M, Okungbowa OE, Lipska A, Jozwik M, et al
    Surface antigen expression on peripheral blood monocytes in women with gynecologic malignancies.
    BMC Cancer. 2015;15:129.
    PubMed     Text format     Abstract available


    January 2015
  71. PYLVAS-EEROLA M, Karihtala P, Puistola U
    Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
    BMC Cancer. 2015;15:493.
    PubMed     Text format     Abstract available


  72. MEYS EM, Rutten IJ, Kruitwagen RF, Slangen BF, et al
    Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlan
    BMC Cancer. 2015;15:482.
    PubMed     Text format     Abstract available


  73. MCEVOY LM, O'Toole SA, Spillane CD, Martin CM, et al
    Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    BMC Cancer. 2015;15:547.
    PubMed     Text format     Abstract available


  74. REN Y, Jiang R, Yin S, You C, et al
    Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study.
    BMC Cancer. 2015;15:583.
    PubMed     Text format     Abstract available


  75. COOKE NM, Spillane CD, Sheils O, O'Leary J, et al
    Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
    BMC Cancer. 2015;15:627.
    PubMed     Text format     Abstract available


  76. SUN F, Ding W, He JH, Wang XJ, et al
    Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    BMC Cancer. 2015;15:746.
    PubMed     Text format     Abstract available


  77. REFKY B, Kotb S, Fady T, Marwan A, et al
    Impact of liver cirrhosis due to chronic hepatitis C viral infection on the outcome of ovarian cancer: a prospective study.
    BMC Cancer. 2015;15:754.
    PubMed     Text format     Abstract available


  78. JATOI A, Foster NR, Kalli KR, Vierkant RA, et al
    Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival.
    BMC Cancer. 2015;15:711.
    PubMed     Text format     Abstract available


  79. ARSENIC R, Braicu EI, Letsch A, Dietel M, et al
    Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.
    BMC Cancer. 2015;15:784.
    PubMed     Text format     Abstract available


  80. ZHOU C, Kang J, Wang X, Wei W, et al
    Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models.
    BMC Cancer. 2015;15:889.
    PubMed     Text format     Abstract available


  81. FOURCADIER E, Tretarre B, Gras-Aygon C, Ecarnot F, et al
    Under-treatment of elderly patients with ovarian cancer: a population based study.
    BMC Cancer. 2015;15:937.
    PubMed     Text format     Abstract available


  82. YAO X, Dong Z, Zhang Q, Wang Q, et al
    Epithelial ovarian cancer stem-like cells expressing alpha-gal epitopes increase the immunogenicity of tumor associated antigens.
    BMC Cancer. 2015;15:956.
    PubMed     Text format     Abstract available


  83. CUI X, Li L, Yan G, Meng K, et al
    High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    BMC Cancer. 2015;15:244.
    PubMed     Text format     Abstract available


  84. CHEN J, Liu Z, Fang S, Fang R, et al
    Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.
    BMC Cancer. 2015;15:91.
    PubMed     Text format     Abstract available


  85. CAO WM, Gao Y, Yang HJ, Xie SN, et al
    Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
    BMC Cancer. 2016;16:64.
    PubMed     Text format     Abstract available


  86. LANE D, Matte I, Garde-Granger P, Laplante C, et al
    Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    BMC Cancer. 2015;15:492.
    PubMed     Text format     Abstract available


  87. CHEN S, Gou WF, Zhao S, Niu ZF, et al
    The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.
    BMC Cancer. 2015;15:471.
    PubMed     Text format     Abstract available


  88. ZHANG Y, Fan S, Xiang Y, Duan H, et al
    Comparison of the prognosis and recurrence of apparent early-stage ovarian tumors treated with laparoscopy and laparotomy: a meta-analysis of clinical studies.
    BMC Cancer. 2015;15:597.
    PubMed     Text format     Abstract available


  89. LI X, Pan Q, Wan X, Mao Y, et al
    Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
    BMC Cancer. 2015;15:509.
    PubMed     Text format     Abstract available


  90. HEMPEN A, Samartzis EP, Kamarachev J, Fink D, et al
    Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report.
    BMC Cancer. 2015;15:507.
    PubMed     Text format     Abstract available


  91. HUANG R, Li X, Holm R, Trope CG, et al
    The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.
    BMC Cancer. 2015;15:502.
    PubMed     Text format     Abstract available


  92. DU J, Li B, Fang Y, Liu Y, et al
    Overexpression of Class III beta-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
    BMC Cancer. 2015;15:536.
    PubMed     Text format     Abstract available


  93. TRENDOWSKI M, Christen TD, Acquafondata C, Fondy TP, et al
    Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
    BMC Cancer. 2015;15:632.
    PubMed     Text format     Abstract available


  94. BURGHAUS S, Haberle L, Schrauder MG, Heusinger K, et al
    Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study.
    BMC Cancer. 2015;15:751.
    PubMed     Text format     Abstract available


  95. HO CM, Huang CJ, Huang SH, Chang SF, et al
    Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
    BMC Cancer. 2015;15:789.
    PubMed     Text format     Abstract available


  96. NISHIMURA T, Nakamura K, Yamashita S, Ikeda S, et al
    Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
    BMC Cancer. 2015;15:957.
    PubMed     Text format     Abstract available


  97. MOTA A, Trivino JC, Rojo-Sebastian A, Martinez-Ramirez A, et al
    Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    BMC Cancer. 2015;15:940.
    PubMed     Text format     Abstract available


    December 2014
  98. TONE AA, McConechy MK, Yang W, Ding J, et al
    Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    BMC Cancer. 2014;14:982.
    PubMed     Text format     Abstract available


  99. WANG Y, Herrstedt J, Havsteen H, DePoint Christensen R, et al
    A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    BMC Cancer. 2014;14:937.
    PubMed     Text format     Abstract available


    November 2014
  100. BRANDALIZE AP, Schuler-Faccini L, Hoffmann JS, Caleffi M, et al
    A DNA repair variant in POLQ (c.-1060A > G) is associated to hereditary breast cancer patients: a case-control study.
    BMC Cancer. 2014;14:850.
    PubMed     Text format     Abstract available


  101. HIRATA Y, Murai N, Yanaihara N, Saito M, et al
    MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
    BMC Cancer. 2014;14:799.
    PubMed     Text format     Abstract available


    September 2014
  102. SEONG MW, Cho SI, Kim KH, Chung IY, et al
    A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients.
    BMC Cancer. 2014;14:645.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: